Kornimate/medical-research-clean huggingface dataset:
community intervention and demonstration area construction

Conditions: Myopia; Refractive Errors

Summary: the objective of this intervention study was to understand the visual health status of nearly one million children and adolescents in ten provinces in china, and then to conduct intervention and evaluate the effect of intervention measures with the development of myopia as the outcome indicator. the study will be conducted in the form of a stepped intervention and will answer the following questions. current china children and adolescent's vision health, including the different degrees of myopia prevalence, and farsightedness reserve status. to evaluate the implementation and effect of eight appropriate technologies and six interventions developed in this study, to reduce the incidence of myopia among children and adolescents in china, to achieve the purpose of nationwide application. in the early stage of this study, a baseline survey will be conducted on participants. in the middle stage, participants will be required to adjust the seat height regularly and increase the time for outdoor activities, etc. in the later stage, intervention measures will be evaluated based on the overall research situation to consider national promotion.


Eligibility criteria:
inclusion criteria: * ● kindergarten kids. * grade of 1 to 6 in elementary schools. * grade of 1 to 3 in middle schools. * grade of 1 to 3 in high schools. * sign the informed consent. exclusion criteria: * ●visual defect or other eye diseases. * wearing orthokeratology; refractive surgery history. * not considered suitable for inclusion in the study by the investigator.
mt2021-27 ft538 recurrent ovarian, fallopian tube, and primary peritoneal cancer

Conditions: Cancer; Solid Tumor; Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Summary: to determine the maximum tolerated dose (mtd) of ft538 monotherapy when administered via intraperitoneal (ip) catheter and in combination with intravenous (iv) enoblituzumab in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer.


Eligibility criteria:
inclusion criteria: * recurrent epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer meeting one of the following minimal prior treatment requirements (no limit to the maximum number of prior treatments). * platinum resistant: may receive ft538 as 2nd line (as 1st salvage therapy). * at least 18 years of age at the time of consent. * gog performance status 0, 1, or 2 (refer to appendix i). * adequate organ function within 14 days (28 days for pulmonary and cardiac) of study treatment (cy/flu or enoblituzumab) start * pulmonary function: oxygen saturation ≥ 90% on room air; pfts are performed only if known history or as medically indicated - if done, must have pulmonary function \>50% corrected dlco and fev1. * cardiac function: lvef ≥ 40% by echocardiography, muga, or cardiac mri; no clinically significant cardiovascular disease including any of the following: stroke or myocardial infarction within 6 months prior to first study treatment; unstable angina or congestive heart failure of new york heart association (nyha) grade 2 or higher (appendix i). exclusion criteria: * pregnant or breastfeeding or planning on becoming pregnant in the next 6 months. * currently receiving or likely to require systemic immunosuppressive therapy * active autoimmune disease requiring systemic immunosuppressive therapy. * history of severe asthma and currently on chronic systemic medications. * uncontrolled bacterial, fungal or viral infections with progression of clinical symptoms despite therapy. * receipt of any biological therapy, chemotherapy, or radiation therapy (except palliative rt), within 2 weeks prior to the first dose of ft538 * live vaccine within 6 weeks prior to start of lympho-conditioning. * known allergy to the following ft538 components: albumin (human) or dimethyl sulfoxide (dmso). * prior enoblituzumab. * non-malignant cns disease such as stroke, epilepsy, cns vasculitis, or neurodegenerative disease or receipt of medications for these conditions in the 2-year period leading up to study enrollment. (refer to section 5.1.8 regarding history of brain metastases.) * known history of hiv positivity or active hepatitis c or b - chronic asymptomatic viral hepatitis is allowed. * presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to patient. * any medical condition or clinical laboratory abnormality that, per investigator judgement, precludes safe participation in and completion of the study or that could affect compliance with protocol conduct or interpretation of results.
multiple-vaccine therapy in treating patients with non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to evaluate the safety, tolerability, immune response and clinical response of different doses of hla-a\*2402 restricted epitope peptides urlc10, ttk, vegfr1 and vegfr2 emulsified with montanide isa 51.

urlc10 and ttk have been identified as cancer specific molecules especially in non small cell lung cancer using genome-wide expression profile analysis by cdna microarray technique. we have determined the hla-a\*2402 restricted epitope peptides derived from these molecules. we also tend to use the peptides targeting to tumor angiogenesis. vegf receptor 1 and 2 are essential targets to tumor angiogenesis, and we identified that peptides derived from these receptors significantly induce the effective tumor specific ctl response in vitro and vivo. according to these findings, in this trial, we evaluate the safety, immunological and clinical response of those peptides.

Eligibility criteria:
inclusion criteria: disease characteristics 1. advanced or recurrent non small cell lung cancer 2. second line or later therapeutic status patient characteristics 1. ecog performance status 0-2 2. life expectancy \> 3 months 3. hla-a\*2402 4. laboratory values as follows 1500/mm3\ 75000/mm3 bilirubin \< 3.0mg/dl asparate transaminase \< 99iu/l alanine transaminase \< 126iu/l creatinine \< 2.2mg/dl 5. able and willing to give valid written informed consent exclusion criteria: 1. active and uncontrolled cardiac disease (includes patients with myocardial infarction within 6 months before entry) 2. pregnancy (woman of child bearing potential) 3. active and uncontrolled infectious disease 4. adrenal cortical steroid hormone dependent status 5. decision of unsuitableness by principal investigator
a study evaluating the efficacy and safety of cp-690,550 in asian subjects with moderate to severe plaque psoriasis

Conditions: Psoriasis

Summary: the primary objective of this study is to compare the efficacy of cp-690,550 (5 mg bid and 10 mg bid) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in asian subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.


Eligibility criteria:
inclusion criteria: * have had a diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to the first screening procedure. * have a pasi score of 12 or greater and a pga score of 3 ("moderate") or 4 ("severe") at baseline (day 1). * considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment). exclusion criteria: * currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed. * have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium. * subjects who cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (uvb or puva) for the study are excluded.

Keywords: tofacitinib cp-690 550 xeljanz jak-inhibitor oral treatment psoriasis vulgaris pruritus itch dlqi moderate severe chronic plaque psoriasis
ild: health outcomes in remote digital monitoring versus usual care

Conditions: Interstitial Lung Disease

Summary: interstitial lung disease (ild) is a collective term for a group of diseases where the lungs become scarred causing breathlessness. this research project will assess if remote digital monitoring of frequent spirometry and pulse oximetry can provide an additional way to monitor ild and provide information to support virtual consultations. outcomes in the remote monitoring group will be compared with usual care alone over 12 months. patients taking part will be randomly allocated to remote digital monitoring or to usual care (with an equal chance of either). remote monitoring will be performed using an app provided by patientmpower ltd which patients will be able to download onto a smartphone or tablet. the study team will provide a spirometer and oximeter for patients to measure their lung function (spirometry) and oxygen saturations. these devices link to the app via bluetooth to record all measurements. patients will be asked to do these measurements three times a week. clinical teams will be asked to review all measurements at least once a fortnight. health outcomes will be described and compared between the two groups.

this study hopes to understand more about how remote digital monitoring of spirometry and pulse oximetry fits within the clinical care of patients with interstitial lung disease. this study will randomise patients to either remote monitoring or usual care and then collect information about the trajectory of their interstitial lung disease treatment and monitoring for the next 12 months to understand the impact of remote monitoring.

Eligibility criteria:
inclusion criteria: * diagnosis of fibrotic interstitial lung disease * aged at least 18 years * owns a smartphone or tablet device * has a mobile telephone number, email address and access to the internet at home * in clinic lung function assessment within 6 months prior to study entry including spirometry and gas transfer measurement * intention to have at least two outpatient clinical reviews (either in person or virtual) within the study observation period of 12 months * willing to allow home monitoring of their health including spirometry and pulse oximetry data * understands how to use mobile technology (eg. has downloaded and used other "apps" on their mobile device; uses email) * demonstrates willingness to measure spirometry and pulse oximetry three times weekly for the duration of the observation period * fluent in english language * written or electronic informed consent exclusion criteria: * unable to fulfil all inclusion criteria * cognitive impairment * history of difficulties performing spirometry at previous clinic testing * contraindications to spirometry (for example previous pneumothorax, unstable cardiac status, known aortic or cerebral aneurysm) * serious concomitant conditions which place the patient at high risk of respiratory distress making them unsuitable to be managed at home. * current or recent (within the last 6 weeks before baseline) participation in another research project
early virtual intervention for infants with cp following hie diagnosis

Conditions: Cerebral Palsy; Hypoxic-Ischemic Encephalopathy; Brain Injuries; Perinatal Hypoxia

Summary: this will be a five year study that will be a prospective, randomized, controlled trial (rct) to assess the effect of a virtual early intervention care delivery model in the provision of therapy to enhance the neurodevelopmental trajectory of infants with brain injury. in addition, the investigators will enhance understanding of the social and parental contributors to outcomes and the early health economic impact of a virtual clinic. the results of this study will help inform the design of a larger, multi-center randomized controlled trial.


Eligibility criteria:
inclusion criteria: 1. diagnosis of moderate to severe hypoxic ischemic encephalopathy as defined based on sarnat criteria 35 2. received therapeutic hypothermia 3. abnormal brain mri (deep grey matter, watershed or mixed patterns of injury) in the first seven days of life 4. greater than or equal to 34 weeks gestation 5. patients are followed by the neonatal follow-up clinic at sickkids 6. abnormal gma (abnormal or absent fidgety movements) at 12 weeks of age exclusion criteria: 1. known or high suspicion of a genetic syndrome 2. residence post-discharge will not be with biological parents 3. limited fluency in english 4. no internet access

Keywords: hie cerebral palsy infant virtual care hypoxic-ischemic encephalopathy follow-up brain injuries perinatal hypoxia
performances evaluation of new fibroscan probes dedicated to morbidly obese patients

Conditions: Obesity, Morbid; Liver Fibrosis

Summary: non-alcoholic fatty liver is a common clinical and histological condition associated with metabolic syndrome in patients with and without excess body weight. it represents the most common cause of liver disease in the western world and it is characterized by an excess accumulation of fatty vacuole within hepatocytes. patients with non-alcoholic fatty liver disease (nafld) can progress to non-alcoholic steatohepatitis (nash), and then into cirrhosis and its complications. the prevalence of hepatic steatosis goes from 16 to 31% in the general population, from 50 to 80% in the obese population and up to 96% in morbidly obese patients. as the majority of obese individuals have nafld, non-invasive and widely applicable screening tools for the assessment of liver fibrosis and steatosis are needed. the detection in early stages is the main predictive factor of the long-term outcome. liver biopsy has traditionally been the gold standard for the assessment of patients with nafld, although the well-known limitations. among the non-invasive tools available in the market, the fibroscan® (echosens™, paris, france) has been shown to be a useful tool for diagnosing fibrosis and steatosis in patients with suspected nafld. the fibroscan® is an ultrasound-based vibration-controlled transient elastography (vcte™) device dedicated to liver stiffness measurement (lsm) and the controlled attenuation parameter (cap). several clinical studies have shown the benefit of measuring hepatic stiffness with the fibroscan® in overweight/moderately obese persons. the ability to identify significant fibrosis and cirrhosis has been demonstrated in normal and overweight patients affected with chronic hepatitis b and c, biliary diseases, alcohol related liver disease and nafld. however, subcutaneous fat attenuates the transmission of shear waves into the liver and the ultrasonic signals used to measure their speed of propagation. when scanning morbidly obese patients (bmi≥35 kg/m²) with the xl+ probe, unreliable results occur mainly due to obesity. therefore, the xl probe has been enabled to expand the applicability of the fibroscan® but, the realization of the xl+ examination is still very difficult in the case of morbidly obese patients. this is why to reduce this failure rate, echosens has worked on developing the xxl probe specifically for measuring the lsm in morbidly obese patients.


Eligibility criteria:
inclusion criteria: * patient must be at least 18 years old * patient must be able to give written informed consent * patient affiliated to a social security system * patients participating in the standard bariatric surgery care program (bariatric surgery criteria defined with bmi ≥ 40 kg / m² or patients with bmi ≥ 35 kg / m² and at least 1 associated co-morbidity exclusion criteria: * patient with presence of ascites * patients with exclusion criteria for bariatric surgery
supervised treadmill intervention to reduce inflammation and depression through exercise in hiv: the stride pilot study

Conditions: Depression; Hiv

Summary: depression in people living with hiv is associated with worse care engagement, drug adherence, and higher rates of pre-mature mortality. the prevalence of depression is three times greater in those with hiv than comparable controls. while antiretroviral therapy (art) enables immune reconstitution, those with depression do worse clinically than those without depression even when controlling for hiv stage. however, treating depression in hiv-infected persons is challenging. even among those virologically suppressed on art, a significant percentage are resistant to standard pharmacotherapy or psychotherapy for depression. the reasons for this are complex and poorly understood. an emerging body of evidence indicates that inflammation may perpetuate depression. given people with hiv have ongoing increased inflammation, this could help explain part of why depression rates are so high in people with hiv. treatments for hiv-associated depression would likely be more effective if they were anti- inflammatory in nature. one possible treatment is exercise. exercise is acutely pro-inflammatory due to catabolism but in the long term is anti-inflammatory. however, few studies have investigated exercise as a treatment for hiv-associated depression. the study objective is to perform a feasibility study to evaluate a larger trial evaluating the efficacy of exercise as an intervention for depression in people with hiv.


Eligibility criteria:
inclusion criteria: * enrolled in mildmay hiv clinic * adults 18-45 years old * hiv positive * receiving hiv therapy * hiv viral suppression (\&lt;400 copies/ml) per chart review * mild to moderate (phq9 score \&gt;5 but \&gt;20) * not currently engaged in a formal exercise program or manual labor such as construction or delivery requiring a manual bike or walking * able to walk/run on a treadmill * informed consent exclusion criteria: * women pregnant or breastfeeding * suicidal (phq-9 question 9 score \>2) or severely depressed (phq-9 score \>20) * uncontrolled hypertension (≥180 systolic or ≥100 diastolic blood pressure) * lower limb orthopedic limitations (e.g. amputations, arthritis) * resting heart rate \>90/min * known atherosclerotic or non-atherosclerotic peripheral artery disease. * exercise intolerance due to other known medical condition(s) which may make it unsafe for the patients to participate in.
can japanese traditional foods lower blood pressure in healthy volunteers

Conditions: Blood Pressure

Summary: the purpose of this study is to determine whether traditional japanese diet blood pressure in healthy volunteers.

japanese traditional diet contains considerably more nitrate/nitrite than the european foods. 80% of dietary nitrate originates from vegetables. green leafy vegetables, especially spinach, salad and seaweed are rich in nitrates. other vegetables contain nitrate at lower concentrations, but because they are consumed in greater quantity, they may contribute more nitrate and thus nitrite from the diet. nitrate/nitrite is attributed multiple health benefits. japanese people have an exceptional longevity and the lowest rate of heart diseases. on the other hand, gastric cancer rate is high too. nitrate/nitrite is strongly correlated with these phenomena. is this high nitrate consumption protective or damaging? understanding dietary nitrite and nitrate consumption and its metabolism therefore becomes very important. aim: to compare conversion of nitrate to nitrite in japanese people, measured in blood and in saliva during consumption of traditional japanese foods vs european diet.

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * high/low blood pressure
randomized study of gonadotropin-releasing-hormone agonist (gnrh-a) or expectant management for endometriosis

Conditions: Endometriosis

Summary: the purpose of this study is to identify the recurrent rate and pregnancy rate of advanced endometriosis after laparoscopic surgery plus gnrha goserelin acetate treatment.

in order to decrease endometriosis recurrence and enhance pregnancy rate after surgical therapy, it has been proposed to use a post-surgical gonadotropin-releasing-hormone agonist (gnrha) treatment. data on the short-term recurrence of advanced endometriosis is rare. although operative treatment has resulted in increasing pregnancy rate comparing non surgery management for moderate to severe endometriosis, very few data of spontaneous pregnancy rate are available comparing gnrha treatment or expectant management after surgery treatment. in this situation, the investigators conduct a prospective, randomized, controlled study to determine whether postoperative gnrha (goserelin acetate) therapy for advanced endometriosis is effective in reducing endometriosis recurrence rate and improving reproductive outcome.

Eligibility criteria:
inclusion criteria: * age \>=18 years old * normal menstruation for 3 months before enrollment (25-35 days） * advanced endometriosis confirmed histologically (r-afs score iii-iv) with laparoscopy or laparotomy-pelvic pain and/or dysmenorrhea and/or dyspareunia * agreement on the strict follow-up plan * without previous hormonal treatment * using nonhormonal method of contraception during this study exclusion criteria: * serious heart diseases/pulmonary/liver/kidney diseases * previous non-endometriosis relevant surgery possibly influence to abdominal or pelvic pain * suspected malignancy in endometriosis * coagulation disorders with hemorrhagic tendency * pregnancy or lactation * allergy to gnrha * previous ineffective treatment with gnrha

Keywords: endometriosis recurrence pregnancy rate laparoscopy gonadotropin-releasing hormone
family planning in inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: this study explores the lived experiences of family planning for women with inflammatory bowel disease (ibd) and their partners during the reproductive stages of pre-conception, pregnancy and the postnatal period through qualitative interviews. insights from existing literature alongside findings from interviews and focus groups with patients and healthcare providers to develop an intervention to address the issues and support needs as identified by study participants.

this study will be conducted in 3 phases: phase 1: literature review (0-9 months). the research literature on pregnancy outcomes and factors affecting family planning decisions of women and men diagnosed with ibd will be systematically searched and reviewed. the findings will be used to prepare a topic guide to be used in the interviews with women and their partners. phase 2: interview study (10-20 months). a topic guide prepared in phase 1 will provide a structure for in-depth interviews to explore the experience of family planning by women diagnosed with inflammatory bowel disease (ibd) and their partners. detailed face-to-face interviews will be voice recorded and transcribed verbatim. each interview may last approximately 45-60 minutes, giving participants sufficient time to share their experience. a total of 24-30 women diagnosed with ibd will be interviewed, where possible selecting 8-10 women at different family planning stages (pre-pregnancy, pregnancy and post-delivery). 3-4 women's partners for in each group, to explore partner's perspective of the pregnancy or pre-conception experience. phase 3: intervention development with focus group interview (21-24 months). the phase 2 findings will be used to prepare a draft of the intervention to address the issues and support needs as identified by study participants. a group of patients (3-4) and healthcare practitioners (3-4) will be recruited to take part in a joint discussion (focus group interview) on intervention acceptability, and the comments will be used to further develop the intervention.

Eligibility criteria:
inclusion criteria: * women diagnosed with ibd at different family planning stages (pre-pregnancy, pregnancy and post-partum). * women diagnosed with ibd's partners. * health practitioners involved with women diagnoses with ibd and on-going care (phase 3 only). exclusion criteria: * does not consent